Fig. 2: Ag+ CD8+ T cell landscape. | Nature Communications

Fig. 2: Ag+ CD8+ T cell landscape.

From: Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients

Fig. 2

A Percentage and absolute number of CD8+ T cells. Dot plots show the percentage and absolute number of CD8+ T cells. The central bar represents the mean ± SD. Kruskal–Wallis test (one-sided) with Benjamini–Hochberg correction for multiple comparisons. Significant adjusted q-values are reported in the figure. B Percentage and absolute number of Ag+ CD8+ T cells. Dot plots show the percentage and absolute number of Ag+ CD8+ T cells. The central bar represents the mean ± SD. Kruskal–Wallis test (one-sided) with Benjamini–Hochberg correction for multiple comparisons. Significant adjusted q-values are reported in the figure. C Ag+ CD8+ T cells phenotype UMAP and Heatmap. Uniform Manifold Approximation and Projection (UMAP) plot shows the 2D spatial distribution of 93.757 cells from healthy donors (HD) and MS patients treated with different DMT embedded with FlowSOM clusters. Heatmap of the median marker intensities of the 10 lineage markers across the 12 cell populations obtained with FlowSOM algorithm after the manual metacluster merging. The colors of cluster_id column correspond to the colors used to label the UMAP plot clusters. The color in the heatmap is referred to the median of the arcsinhmarker expression (0–1 scaled) calculated over cells from all of the samples. Blue represents lower expression, while red represents higher expression. Light gray bar along the rows (clusters) and values in brackets indicate the relative sizes of the clusters. N naive, TSCM T stem cell memory, CM central memory, TM transitional memory, EM effector memory, EMRA effector memory reexpressing the CD45RA, cTfh circulating T follicular helper cells. D UMAP graphs stratified by therapy: healthy donors (HD); Cladribine; Dimethyl Fumarate (DMF); DMF Lymphopenic; Fingolimod; interferon 1β (IFN); Natalizumab; Teriflunomide; Rituximab/Ocrelizumab. E Dot plots of different subpopulation of Ag+ T cells in patients treated with different DMT. The central bar represents the mean ± SD. Kruskal–Wallis test with Benjamini–Hochberg correction for multiple. In A–E plots: HD: n = 13; Cladribine: n = 6; DMF: n = 14; DMF Lymphopenic: n = 9; Fingolimod: n = 12; IFN: n = 13; Natalizumab: n = 15; Teriflunomide: n = 8; Rituximab/Ocrelizumab: n = 11.

Back to article page